305 related articles for article (PubMed ID: 33556177)
1. Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
Graillon T; Ferrer L; Siffre J; Sanson M; Peyre M; Peyrière H; Mougel G; Autran D; Tabouret E; Figarella-Branger D; Barlier A; Kalamarides M; Dufour H; Colin T; Chinot O
Neuro Oncol; 2021 Jul; 23(7):1139-1147. PubMed ID: 33556177
[TBL] [Abstract][Full Text] [Related]
2. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
Graillon T; Tabouret E; Chinot O
Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
[TBL] [Abstract][Full Text] [Related]
4. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Graillon T; Defilles C; Mohamed A; Lisbonis C; Germanetti AL; Chinot O; Figarella-Branger D; Roche PH; Adetchessi T; Fuentes S; Metellus P; Dufour H; Enjalbert A; Barlier A
J Neurooncol; 2015 Aug; 124(1):33-43. PubMed ID: 26015296
[TBL] [Abstract][Full Text] [Related]
6. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
9. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
12. Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
Le Van T; Graillon T; Jacob J; Vauleon E; Feuvret L; Boch AL; Boetto J; Boone M; Bronnimann C; Caire F; De Barros A; Delaitre M; Di Stefano AL; Dore M; Ducray F; Dufour C; Engelhardt J; Fontaine D; Froelich S; Helleringer M; Huchet A; Joncour A; Jouanneau E; Mallereau CH; Monfilliette A; Le Fur E; Zemmoura I; Chinot O; Sanson M; Kalamarides M; Loiseau H; Peyre M
J Neurooncol; 2021 May; 153(1):55-64. PubMed ID: 33778930
[TBL] [Abstract][Full Text] [Related]
13. Treatment of unresectable skull base meningiomas with somatostatin analogs.
Schulz C; Mathieu R; Kunz U; Mauer UM
Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
15. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Chamberlain MC; Glantz MJ; Fadul CE
Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.
Ferraro DJ; Funk RK; Blackett JW; Ju MR; DeWees TA; Chicoine MR; Dowling JL; Rich KM; Drzymala RE; Zoberi I; Simpson JR; Jaboin JJ
Radiat Oncol; 2014 Jan; 9():38. PubMed ID: 24467972
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
18. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
[TBL] [Abstract][Full Text] [Related]
19. Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm.
Valery CA; Faillot M; Lamproglou I; Golmard JL; Jenny C; Peyre M; Mokhtari K; Mazeron JJ; Cornu P; Kalamarides M
J Neurosurg; 2016 Dec; 125(Suppl 1):89-96. PubMed ID: 27903189
[TBL] [Abstract][Full Text] [Related]
20. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
